Initiation of autoimmunity by a reactive metabolite of a lupus-inducing drug in the thymus

Environmental Health Perspectives

Volumn 107, Issue SUPPL. 5, 1999, Pages 803-806

  Rubin, Robert L ^a   Kretz Rommel, Anke ^a  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

Author keywords

Autoantibodies; Drug induced; Lupus; Reactive drug metabolites; T cells; Thymus

Indexed keywords

AUTOANTIBODY; CHLORPROMAZINE; DRUG; DRUG METABOLITE; HYDRALAZINE; HYDROXYLAMINE; ISONIAZID; MYELOPEROXIDASE; PROCAINAMIDE; REACTIVE OXYGEN METABOLITE;

AUTOIMMUNITY; CHROMATIN; CONFERENCE PAPER; DRUG OXIDATION; HUMAN; IMMUNOLOGICAL TOLERANCE; LEUKOCYTE ACTIVATION; LUPUS VULGARIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE; THYMUS;

EID: 0032702789     PISSN: 00916765     EISSN: None     Source Type: Journal    
DOI: 10.1289/ehp.99107s5803     Document Type: Conference Paper

References (41)

1. Dustan HP, Taylor RD, Corcoran AC, Page IH. Rheumatic and febrile syndrome during prolonged hydralazine treatment. JAMA 154:23-29 (1954).
2. Morrow JD, Schroeder HA, Perry HM Jr. Studies on the control of hypertension by hyphex. II: Toxic reactions and side effects. Circulation 8:829-839 (1953).
3. Pohl LR, Satoh H, Christ DD, Kenna JG. The immunologic and metabolic basis of drug hypersensitivities. Ann Rev Pharmacol 28:367-387 (1988).
4. Rawlins MD. Clinical pharmacology. Adverse reactions to drugs. Br Med J 282:974-976 (1981).
5. Uetrecht JP, Sweetman BJ, Woosley RL, Oates JA. Metabolism of procainamide to a hydroxylamine by rat and human hepatic microsomes. Drug Metab Dispos 12:77-81 (1984).
6. Budinsky RA, Roberts SM, Coates EA, Adams L, Hess EV. The formation of hydroxylamine by rat and human liver microsomes. Drug Metab Disp 15:37-43 (1987).
7. Roberts SM, Adams LE, Donovan-Brand R, Budinsky R, Skoulis NP, Zimmer H, Hess EV. Procainamide hydroxylamine lymphocyte toxicity - 1. Evidence for participation by hemoglobin. Int J Immunopharmacol 11:419-427 (1989).
8. Streeter AJ, Timbrell JA. Enzyme-mediated covalent binding of hydralazine to rat liver microsomes. Drug Metab Dispos 11:179-183 (1983).
9. Hein DW, Weber WW. Metabolism of procainamide, hydralazine, and isoniazid in relation to autoimmune(-like) reactions. In: Autoimmunity and Toxicology: Immune Deregulation Induced by Drugs and Chemicals (Kammueller ME, Bloksma N, Seinen N, eds) Amsterdam:Elsevier Science, 1989:239-265.
10. Adams LE, Sanders CE Jr, Budinsky RA, Donovan-Brand R, Roberts SM, Hess EV. Immunomodulatory effects of procainamide metabolites: their implications in drug-related lupus. J Lab Clin Med 113:482-492 (1989).
11. Uetrecht JP. Reactivity and possible significance of hydroxylamine and nitroso metabolites of procainamide. J Pharmacol Exp Ther 232:420-425 (1985).
12. Rubin RL, Uetrecht JP, Jones JE. Cytotoxicity of oxidative metabolites of procainamide. J Pharmacol Exp Ther 242:833-841 (1987).
13. Magner-Wróbel K, Toborek M, Drózdz M, Danch A. Increase in antioxidant activity in procainamide-treated rats. Pharmacol Toxicol 72:94-37 (1993).
14. Rubin RL, Jones JE, Uetrecht JP. Metabolism of procainamide to the reactive hydroxylamine by leukocytes. Fed Proc 46:1380A (1987).
15. Uetrecht JP, Zahid N, Rubin RL. Metabolism of procainamide to a hydroxylamine by human neutrophils and mononuclear leukocytes. Chem Res Toxicol 1:74-78 (1988).
16. Rubin RL, Curnutte JT. Metabolism of procainamide to the cytotoxic hydroxylamine by neutrophils activated in vitro. J Clin Invest 63:1336-1343 (1989).
17. Jiang X, Khursigara G, Rubin RL. Transformation of lupus-inducing drugs to cytotoxic products by activated neutrophils. Science 266:810-813 (1994).
18. Kelder PP, De Moal NJ, Hart BA, Janssen LHM. Metabolic activation of chlorpromazine by stimulated human polymorphonuclear leukocytes. Induction of covalent binding of chlorpromazine to nucleic acids and proteins. Chem Biol Interact 79:15-30 (1991).
19. Barr DP, Aust SD. On the mechanism of peroxidase-catalyzed oxygen production. Arch Biochem Biophys 303:377-382 (1993).
20. Waldhauser L, Uetrecht J. Oxidation of propylthiouracil to reactive metabolites by activated neutrophils. Implications for agranulocytosis. Drug Metab Dispos 19:354-359 (1991).
21. Hofstra AH, Li-Muller SMA, Uetrecht JP. Metabolism of isoniazid by activated leukocytes. Possible role in drug-induced lupus. Drug Metab Dispos 20:205-210 (1992).
22. Uetrecht J, Sokoluk B. Comparative metabolism and covalent binding of procainamide by human leukocytes. Drug Metab Dispos 20:120-123 (1992).
23. Hofstra AH, Matassa LC, Uetrecht JP. Metabolism of hydralazine by activated leukocytes: implications for hydralazine-induced lupus. J Rheumatol 18:1673-1680 (1991).
24. 1 combinations differing at the major histocompatibility complex. Transplant Rev 31:156-224 (1976).
25. Yamamoto K, Kawanishi S. Free radical production and site-specific DNA damage induced by hydralazine in the presence of metal ions or peroxidase/hydrogen peroxide. Biochem Ptiamacol 41:905-914 (1991).
26. Wheeler JF, Lunte CE, Heineman WR, Adams L, Hess EV. Electrochemical determination of N-oxidized procainamide metabolites and functional assessment of effects on murine cells in vitro [Rapid Communication]. Proc Soc Exp Biol Med 188:381-386 (1988).
27. Adams LE, Roberts SM, Carter JM, Wheeler JF, Zimmer HW, Donovan-Brand RJ, Hess EV. Effects of procainamide hydroxylamine on generation of reactive oxygen species by macrophages and production of cytokines. Int J Immunopharmacol 12:809-819 (1990).
28. Kubicka-Muranyi M, Goebels R, Goebel C, Uetrecht J, Gleichmann E. T lymphocytes ignore procainamide, but respond to its reactive metabolites in peritoneal cells: demonstration by the adoptive transfer popliteal lymph node assay. Toxicol Appl Pharmacol 122:88-94 (1993).
29. + T cells with either of two distinct DNA methyltransferase inhibitors, 5-azacytidine or procainamide, is sufficient to induce a lupuslike disease in syngeneic mice. J Clin Invest 92:38-52 (1993).
30. Yung RL, Quddus J, Chrisp CE, Johnson KJ, Richardson BC. Mechanisms of drug-induced lupus. I: Cloned Th2 cells modified with DNA methylation inhibitors in vitro cause autoimmunity in vivo. J Immunol 154:3025-3035 (1995).
31. Gleichmann E, Pals ST, Rolink AG, Radaskiewicz T, Gleichmann H. Graft-versus-host reactions: clues to the etiopathology of a spectrum of immunological diseases. Immunol Today 5:324-332 (1984).
32. Steinmann GG. Changes in the human thymus during aging. Currrent Topics Pathol 75:43-88 (1986).
33. Watanabe Y, Naiki M, Wilson T, Godfrey D, Chiang B-L, Boyd R, Ansari A, Gershwin ME. Thymic microenvironmental abnormalities and thymic selection in NZB.H-2bm12 mice. J Immunol 150:4702-4712 (1993).
34. β genes in aging mice. J Immunol 149:230-236 (1992).
35. Pircher H, Rohrer UH, Moskophidis D, Zinkernagel RM, Hengartner H. Lower receptor avidity required for thymic clonal deletion than for effector T-cell function. Nature 351:482-485 (1991).
36. Mackall CL, Punt JA, Morgan P, Farr AG, Gress RE. Thymic function in young/old chimeras: substantial thymic T-cell regernerative capacity despite irreversible age-associated thymic involution. Eur J Immunol 28:1886-1893 (1998).
37. Bartho J-M, Demarquay C, Moulian N, van der Meeren A, Berrih-Aknin S, Gourmelon P. Phenotypic and immunohistological analyses of the human adult thymus: evidence for an active thymus during adult life. Cell Immunol 170:30-40 (1997).
38. Weinberg K, Annett G, Kashyap A, Lenarsky C, Forman SJ, Parkman R. The effect of thymic function on immunocompetence following bone marrow transplantation. Biol Blood Marrow Transp 1:18-23 (1995).
39. Douek DC, McFarland RD, Keiser PH, Gage EA, Massey JM, Haynes BF, Polis MA, Haase AT, Feinberg MB, Sullivan JL, et al. Changes in thymic function with age and during the treatment of HIV infection. Nature 396:690-695 (1998).
40. Kretz-Rommel A, Duncan SR, Rubin RL. Autoimmunity caused by disruption of central T-cell tolerance: a murine model of drug-induced lupus. J Clin Invest 99:1888-1896 (1997).
41. Kretz-Rommel A, Rubin RL. Persistence of autoreactive T cell drive in required to elicit anti-chromatin antibodies in a murine model of drug-induced lupus. J Immunol 162:813-820 (1999).